$Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children$

Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children

Background & Aims. Despite significant success in the treatment of acute lymphoblastic leukemia (ALL) in children, relapses and drug resistance to the standard therapy remain the main cause of treatment failure. The addition of bortezomib to the combination therapy of relapsed ALL to change the...

Full description

Saved in:

Bibliographic Details
Main Authors:	NA Batmanova, MA Shervashidze, AV Popa, LYu Grivtsova, IN Serebryakova, GL Mentkevich
Format:	Article
Language:	Russian
Published:	Practical Medicine Publishing House 2017-07-01
Series:	Клиническая онкогематология
Subjects:	acute lymphoblastic leukemia refractoriness relapses bortezomib
Online Access:	http://bloodjournal.ru/wp-content/uploads/2017/09/11.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review
by: Mei Zhou, et al.
Published: (2025-07-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Efficacy and safety of blinatumomab in Chinese patients with relapsed/refractory B-cell acute lymphoblastic leukemia: a single-center retrospective study
by: Yan Wang, et al.
Published: (2025-05-01)

FLAG with Bortezomib in Children and Adolescents with Relapsed/Refractory Acute Myeloid Leukemia in a Resource-Limited Setting: A Single-Center Experience from India
by: Dipesh Dave, et al.

The efficacy of bortezomib during induction therapy in patients with high-risk acute lymphoblastic leukemia
by: Camila Terreros-Palacios, et al.
Published: (2025-07-01)

Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia
by: Tingting Yang, et al.
Published: (2025-01-01)

Treatment of Relapsed and Refractory Hodgkin’s Lymphoma in Children
by: NS Kulichkina, et al.
Published: (2016-01-01)

Treatment of pediatric relapsed and refractory acute myeloid leukemia
by: F. A. Makhacheva, et al.
Published: (2023-05-01)

Successful treatment of two cases with Philadelphia-chromosome positive acute lymphoblastic leukemia who relapsed after allogeneic stem cell transplantation and the treatments with novel immunotherapies and ponatinib
by: Takayoshi Tachibana, et al.
Published: (2024-12-01)

Evaluation of Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Using EuroFlow Approaches
by: OA Beznos, et al.
Published: (2017-04-01)

X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL
by: Michela Carlet, et al.
Published: (2022-11-01)

Diagnosis of Acute Lymphoblastic Leukemia Originating From T-Lineage Precursors and Approaches to Minimal Residual Disease Monitoring
by: OA Chernysheva, et al.
Published: (2018-12-01)

CREBBP is a Major Prognostic Biomarker for Relapse in Childhood B-cell Acute Lymphoblastic Leukemia: A National Study of Unselected Cohort
by: Krstevska Bozhinovikj E, et al.
Published: (2025-03-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Native and pegylated forms of L-asparaginase: the assessment of effectiveness and toxicity in acute lymphoblastic leukemia treated with Berlin–Frankfurt–Munster (BFM) protocol
by: M. A. Shervashidze, et al.
Published: (2024-12-01)

Ocular involvement in pediatric patients with acute leukemia relapse: points of diagnosis and treatment
by: G. A. Radzhabova, et al.
Published: (2025-03-01)

Low Dose Cytarabine and Cladribine for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Clinical Experience
by: SV Gritsaev, et al.
Published: (2016-01-01)

Complete Remission with Inotuzumab Ozogamicin as Fourth-Line Salvage Therapy in a Child with Relapsed/Refractory Acute Lymphoblastic Leukemia
by: Athanasios Tragiannidis, et al.
Published: (2024-09-01)

Revumenib as A New Therapeutic Intervention for Relapsed or Refractory KMT2A-Rearranged Acute Lymphoblastic Leukemia
by: Khushbakht Baloch, et al.
Published: (2025-04-01)

Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutations
by: Bhavana Bhatnagar, et al.
Published: (2025-04-01)

Updates in novel immunotherapeutic strategies for relapsed/refractory AML
by: Sawyer Bawek, et al.
Published: (2024-12-01)

The Use of Ibrutinib in Refractory Chronic Lymphocytic Leukemia and in High-Risk Patients
by: NV Kurkina, et al.
Published: (2019-05-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)

Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center
by: Ziyi Hao, et al.
Published: (2024-12-01)

Pediatric acute lymphoblastic leukemia treatment protocols improvement: emphasis on minimal residual disease
by: M. A. Shervashidze, et al.
Published: (2020-10-01)

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Acute lymphoblastic leukemia with eosinophilia: diagnostic and treatment features
by: O. D. Gurieva, et al.
Published: (2025-05-01)

Toxicity assessment of acute lymphoblastic leukemia treatment protocol ALL IC-BFM 2002
by: T. T. Valiev, et al.
Published: (2022-07-01)

Efficacy and safety of venetoclax combination therapy for relapsed/refractory acute myeloid leukemia: a systematic review and meta-analysis
by: Ning Jiao, et al.
Published: (2024-10-01)

Surveillance and expected outcome of acute lymphoblastic leukemia in children and adolescents: An experience from Eastern India
by: Ashis Mukhopadhyay, et al.
Published: (2013-01-01)

Case Report: CD19 CAR-T cells derived from recipient of umbilical cord blood transplantation effectively treated relapsed acute lymphoblastic leukemia after UCBT
by: Hua Li, et al.
Published: (2025-05-01)

Thyroiditis mimicking relapse of acute lymphoblastic leukemia: Gallium-67 scan suggested the diagnosis
by: Othman Saleh
Published: (2010-01-01)

Combination of hypomethylating agents and inhibitor of BCL-2 in treatment of patients with relapsed acute myeloid leukemia: S.P. Botkin hospital experience
by: M. A. Granatkin, et al.
Published: (2023-03-01)

Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial
by: Ya‐Lan Zhou, et al.
Published: (2025-04-01)

Hepatic Dysfunction during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma and Its Effects on Subsequent Therapy and Outcome
by: Nalla Anuraag Reddy, et al.
Published: (2024-04-01)

Infant lymphoblastic leukemia: a single centers 10 year experience
by: İnci Yaman-Bajin, et al.
Published: (2019-06-01)

Efficacy and safety of mitoxantrone hydrochloride liposome-containing regimens in treating refractory/relapsed acute myeloid leukemia
by: Ni Lu, et al.
Published: (2025-05-01)

Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia
by: Hui-Sheng Zhou, et al.
Published: (2025-04-01)

Hemostasis defects correction in children with acute lymphoblastic leukemia
by: A. S. Roshik, et al.
Published: (2022-11-01)

Radiation-induced hypopituitarism in children with acute lymphoblastic leukemia
by: Mehrdad Mirouliaei, et al.
Published: (2013-01-01)